“Valve in valve” implantation of two self-expandable transcatheter aortic valves in a patient with aortic root aneurysm and massive aortic regurgitation: “A new TAVI option”

2013 ◽  
Vol 83 (5) ◽  
pp. 836-840 ◽  
Author(s):  
Gabriele Pesarini ◽  
Francesco Bedogni ◽  
Flavio Ribichini
2012 ◽  
Vol 5 (5) ◽  
pp. 689-697 ◽  
Author(s):  
Axel Linke ◽  
Felix Woitek ◽  
Marc W. Merx ◽  
Conrad Schiefer ◽  
Sven Möbius-Winkler ◽  
...  

2020 ◽  
Vol 7 (12) ◽  
pp. 201838
Author(s):  
Romina Plitman Mayo ◽  
Halit Yaakobovich ◽  
Ariel Finkelstein ◽  
Shawn C. Shadden ◽  
Gil Marom

Leaflet thrombosis has been suggested as the reason for the reduced leaflet motion in cases of hypoattenuated leaflet thickening of bioprosthetic aortic valves. This work aimed to estimate the risk of leaflet thrombosis in two post-valve-in-valve (ViV) configurations, using five different numerical approaches. Realistic ViV configurations were calculated by modelling the deployments of the latest version of transcatheter aortic valve devices (Medtronic Evolut PRO, Edwards SAPIEN 3) in the surgical Sorin Mitroflow. Computational fluid dynamics simulations of blood flow followed the dry models. Lagrangian and Eulerian measures of near-wall stagnation were implemented by particle and concentration tracking, respectively, to estimate the thrombogenicity and to predict the risk locations. Most of the numerical approaches indicate a higher leaflet thrombosis risk in the Edwards SAPIEN 3 device because of its intra-annular implantation. The Eulerian approaches estimated high-risk locations in agreement with the wall sheer stress (WSS) separation points. On the other hand, the Lagrangian approaches predicted high-risk locations at the proximal regions of the leaflets matching the low WSS magnitude regions of both transcatheter aortic valve implantation models and reported clinical and experimental data. The proposed methods can help optimizing future designs of transcatheter aortic valves with minimal thrombotic risks.


2014 ◽  
Vol 7 (7) ◽  
pp. e71-e72 ◽  
Author(s):  
Jan-Malte Sinning ◽  
Mariuca Vasa-Nicotera ◽  
Nikos Werner ◽  
Sebastian Zimmer ◽  
Fritz Mellert ◽  
...  

2012 ◽  
Vol 5 (5) ◽  
pp. 571-577 ◽  
Author(s):  
Stefan Toggweiler ◽  
David A. Wood ◽  
Josep Rodés-Cabau ◽  
Samir Kapadia ◽  
Alexander B. Willson ◽  
...  

2015 ◽  
Vol 20 (6) ◽  
pp. 694-700 ◽  
Author(s):  
Christoph Huber ◽  
Fabien Praz ◽  
Crochan J. O'Sullivan ◽  
Bettina Langhammer ◽  
Steffen Gloekler ◽  
...  

2021 ◽  
Vol 42 (Supplement_1) ◽  
Author(s):  
N Schamroth Pravda ◽  
P Codner ◽  
H Vaknin Assa ◽  
G Vitberg ◽  
L Perl ◽  
...  

Abstract Introduction The Valve-in-Valve (ViV) technique is an established alternative for the treatment of structural bioprosthetic valve deterioration (SVD). Data describing the long term follow up of patients treated with this approach is scarce. We report on our long-term follow up outcomes of patients with SVD in the Aortic position treated with ViV. Methods Included were patients with symptomatic SVD in the aortic position valve who were treated by Valve in valve transcatheter aortic valve implantation (ViV-TAVI) during the years 20102019 in our center. Three main outcomes were examined during follow up: NYHA functional class, hemodynamic of the VIV-TAVI per echocardiography, and overall mortality. Results Our cohort consisted of 84 patients (mean age 78.8±8.9 years). The indications for aortic ViV were: SVD isolated aortic stenosis in 37.6%, SVD isolated aortic regurgitation in 42.2% and combined valve pathology in 20.0%. Self-expandable and balloon-expandable devices were used in 73 (85.9%) and 12 (14.1%), respectively. Average time of follow up was 3.74±2.4 years. 95% and 91% of patients were in NYHA functional class I/II at 1 and 5 year follow up respectively. At one year the mean trans-aortic valve pressure was 15.3±9.3 and rates of ≥ moderate aortic regurgitation were 3.7%. Survival was 91.4% (95% CI 85.6–97.7) at one year and 79.5% (95% CI 70.2–90.0) at 3 years. Conclusion ViV in the aortic position offers an effective and durable treatment option for patient with SVD, with low rates of all-cause mortality, excellent hemodynamic and improved functional capacity at 3 years follow up. FUNDunding Acknowledgement Type of funding sources: None. NYHA functional class over follow up


Sign in / Sign up

Export Citation Format

Share Document